Insider · CIK 0001820836
John C Jacobs
Files at NVAX (NOVAVAX INC). First filing -, latest -.
In brief
John C Jacobs files SEC Form 4 as CEO, president and director at NVAX (NOVAVAX INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John C Jacobs has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Non-Statutory Stock Option NQderivative | +551,500 | $0.00 | $0 | 551,500 | Mar 9, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | MOption exercise Common Stock | +150,167 | $0.00 | $0 | 264,130 | Mar 5, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | FTax withholding Common Stock | -69,288 | $9.49 | $658k | 225,680 | Mar 5, 2026 |
| Mar 3, 2026 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -150,167 | $0.00 | $0 | 300,333 | Mar 5, 2026 |
| Mar 1, 2026 | NVAX NOVAVAX INC | MOption exercise Common Stock | +83,333 | $0.00 | $0 | 264,130 | Mar 3, 2026 |
| Mar 1, 2026 | NVAX NOVAVAX INC | FTax withholding Common Stock | -38,450 | $10.14 | $390k | 225,680 | Mar 3, 2026 |
| Mar 1, 2026 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -83,333 | $0.00 | $0 | 0 | Mar 3, 2026 |
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Restricted Stock Unitsderivative | +367,500 | $0.00 | $0 | 367,500 | Mar 3, 2026 |
| Mar 2, 2026 | NVAX NOVAVAX INC | AGrant or award Non-Statutory Stock Option NQderivative | +551,500 | $9.09 | $5.0M | 551,500 | Mar 3, 2026 |
| Jan 23, 2026 | NVAX NOVAVAX INC | MOption exercise Common Stock | +83,197 | $0.00 | $0 | 219,929 | Jan 26, 2026 |
| Jan 23, 2026 | NVAX NOVAVAX INC | FTax withholding Common Stock | -39,132 | $9.17 | $359k | 180,797 | Jan 26, 2026 |
| Jan 23, 2026 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -83,197 | $0.00 | $0 | 0 | Jan 26, 2026 |
| Mar 3, 2025 | NVAX NOVAVAX INC | AGrant or award 2025 Non-statutory Stock Option NQderivative | +676,000 | $7.87 | $5.3M | 676,000 | Mar 5, 2025 |
| Mar 3, 2025 | NVAX NOVAVAX INC | AGrant or award 2025 Restricted Stock Units RSUderivative | +450,500 | $0.00 | $0 | 450,500 | Mar 5, 2025 |
| Mar 1, 2025 | NVAX NOVAVAX INC | MOption exercise Common Stock | +83,334 | $0.00 | $0 | 175,183 | Mar 4, 2025 |
| Mar 1, 2025 | NVAX NOVAVAX INC | FTax withholding Common Stock | -38,451 | $8.33 | $320k | 136,732 | Mar 4, 2025 |
| Mar 1, 2025 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -83,334 | $0.00 | $0 | 166,666 | Mar 4, 2025 |
| Jan 23, 2025 | NVAX NOVAVAX INC | MOption exercise Common Stock | +83,196 | $0.00 | $0 | 130,722 | Jan 27, 2025 |
| Jan 23, 2025 | NVAX NOVAVAX INC | FTax withholding Common Stock | -38,873 | $9.55 | $371k | 91,849 | Jan 27, 2025 |
| Jan 23, 2025 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -83,196 | $0.00 | $0 | 83,197 | Jan 27, 2025 |
Questions about John C Jacobs
Answered from the filings on this page, as of the latest one.
Is John C Jacobs buying or selling?
John C Jacobs has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John C Jacobs's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John C Jacobs has 0.
Where does John C Jacobs file Form 4?
John C Jacobs has filed Form 4 at NVAX (NOVAVAX INC) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.